TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01645423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium Tablets, 80 mg
Description: Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
Study: NCT02363452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir
Description: Oral Solution (syrup) or Tablets
Study: NCT02541591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuroprotective goal directed hemodynamic optimization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MAP > 65mmHg
Description: MAP \> 65mmHg
Study: NCT03323957

Intervention type: DIAGNOSTIC_TEST
Intervention: nutritional screening tool
Description: screening of disease associated malnutrition in sick infants
Study: NCT03232788

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone regeneration
Description: Autogenous bone will be placed over periodontal defect after root treatment with scaling and root planing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone regeneration
Description: Autogenous bone will be placed over periodontal defect after root treatment with scaling and root planing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen membrane
Description: A collagen membrane will be used to cover the autogenous bone.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scaffold
Description: A hydroxyapatite and polycaprolactone scaffolds will be used to cover the autogenous bone.
Study: NCT03399448

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1
Description: Autologous T cells transduced with a lentiviral vector to express NY-ESO-1 and electroporated with CRISPR guide RNA to disrupt expression of endogenous TCRα, TCRβ and PD-1 (NYCE T Cells).
Study: NCT03804398

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEEP level of 5 cmH2O
Description: In the control group at PEEP level of 5 cmH2O was established and maintained during the study period
Study: NCT04030494

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: BP measurement
Description: sequential BP measurement with Withings WPM04 and sphygmomanometer with dual observer auscultation

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: BP measurement
Description: sequential BP measurement with Withings WPM04 and sphygmomanometer with dual observer auscultation

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AF detection
Description: single lead ECG with Withings WPM04 and 12 lead ECG

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AF detection
Description: single lead ECG with Withings WPM04 and 12 lead ECG

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: VHD detection
Description: phonocardiogram with digital stethoscope of Withings WPM04 and Doppler echocardiography

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: VHD detection
Description: phonocardiogram with digital stethoscope of Withings WPM04 and Doppler echocardiography

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: VHD detection
Description: phonocardiogram with digital stethoscope of Withings WPM04 and Doppler echocardiography
Study: NCT02610816

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1 Food Elimination Diet
Description: Participants eliminate milk from the diet for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4 Food Elimination Diet
Description: Participants eliminate milk, egg, wheat, soy from the diet for 12 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: 4 Food Elimination Diet (post 1FED failure)
Description: Participants that fail to respond to 1FED in phase 1 eliminate milk, egg, wheat, soy from the diet for 12 weeks in Phase 2

Intervention type: DRUG
Group type: OTHER
Intervention: Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)
Description: Participants that fail to respond to 4FED in phase 1 administer swallowed glucocorticosteroids (Flovent HFA) 800 mcg twice daily for 12 weeks in Phase 2
Study: NCT02032251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral administration of ginger
Description: Oral administration of ginger in patients with infertility.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00789269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhubarb
Description: 14 days of rhubarb

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 14 days of placebo
Study: NCT03026335

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Action
Description: Based upon a Cognitive Behavioral Therapy model, intervened schools were engaged in providing curriculum, school infrastructure elements, and parent/community involvement activities around a single model aimed to provide positive support for behaviors. Six areas were identified: self-concept, body/mind, responsible self-management, treating others they way you want to be treated, telling yourself the truth, and continual improvement of self.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Business as usual with students in non-itervened schools
Study: NCT04448093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental treatment
Description: Dental treatment of adequacy of oral environment and assessment of quality of life and self-esteem through questionnaires comparing a group that received treatment with another that did not.
Study: NCT03268694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working Memory Task
Description: Sternberg Task Items, which can be visually presented alphabets, shapes or numbers or sound tones presented through speakers, will be presented to the participant. The participant will need to maintain the presented items in their memory and indicate, when a single probe item is presented, whether the probe item was present in the immediately preceding list by pressing a key on the keyboard.~N-Back Task Items are presented continuously sequentially and participants are instructed to indicate whether items are repeated n items before by pressing a key on the keyboard. The task is divided into blocks of 0,1,2,3 -back trials based on the 'n'. For example in the 2 - back task, the participant has to indicate if the item presented 2 items before matches the current item. Similar to the previous task, the items can be presented visually or auditorily.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reward Learning Task
Description: Two abstract visual stimuli are presented on the screen and participant is asked to choose one. Unknown to the participant, each stimulus is associated with distinct probabilities of virtual reward such that one stimulus is associated with net gain while the other is associated with net loss. The participant's goal is to maximize the reward. Once the participant identifies the stimulus associated with net gain, the reward probabilities are reversed. This process is repeated 5 times.
Study: NCT00734201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V24343
Description: Oral, 1mg, 2 mg, 5 mg or 25 mg, or placebo, once daily for 28 days
Study: NCT03268694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial Emotion Recognition Task
Description: On a given trial, participants will be presented with images of two faces side-by-side. The faces will either match in terms of emotion category (e.g., 2 anger faces) or not (e.g., an anger face and a fear face). Faces presented together will always be of the same gender but different identities. Participants will be asked to determine whether the two faces presented depict the same emotion category.
Study: NCT04380974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCTA plus OCT guided 3+PRN regimen
Description: For the OCTA plus OCT guided 3+PRN regimen, we recorded patients' data after retreatment by 3 monthly intravitreal injections of anti-VEGF drug. Subsequent reinjections were given as needed according to the changes in patients' visual acuity, activity of PCV lesions shown by OCTA and/or the exudation shown by OCT. Four weeks after the third and last injection, all patients in this group underwent an examination, including ETDRS visual acuity, fundus photography, OCTA and OCT.~In case of BVN increased or polypoidal lesion progressed on OCTA scans, persistent subfoveal or perifoveal fluid, macular intraretinal edema on OCT scans, or visual loss of \>5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OCT guided 3+PRN regimen
Description: For the OCT guided 3+PRN group, we recorded patients'data after retreatment by 3 monthly intravitreal injections of Anti-VEGF drugs. Subsequent reinjections were given as needed according to the changes in patients'visual acuity and/or the exudation shown by OCT. Four weeks after the third and last injection, all patients in this group underwent an examination, including ETDRS visual acuity, fundus photography, and OCT.~In case of persistent subfoveal or perifoveal fluid, macular intraretinal edema, visual loss of \>5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-VEGF drug
Description: Conbercept or other anti-VEGF drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF drug
Description: Conbercept or other anti-VEGF drugs
Study: NCT04706429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trientine
Description: Trientine dihydrochloride is a white to pale yellow crystalline hygroscopic powder.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, manufactured with the exact components of the trientine capsules, without the active ingredient / investigational medicinal product.
Study: NCT01611350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RCT 1- Testing the Effectiveness of Marketing Messages in Increasing Willingness to Pay
Description: We are testing whether any marketing messages effect participants willingness to pay for the fuel efficient cookstoves. All marketing messages are true.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RCT 1- Testing the Effectiveness of Marketing Messages in Increasing Willingness to Pay
Description: We are testing whether any marketing messages effect participants willingness to pay for the fuel efficient cookstoves. All marketing messages are true.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RCT 1- Testing the Effectiveness of Marketing Messages in Increasing Willingness to Pay
Description: We are testing whether any marketing messages effect participants willingness to pay for the fuel efficient cookstoves. All marketing messages are true.
Study: NCT01252719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single-Dose IV Oritavancin Diphosphate
Description: Oritavancin was administered as a single IV dose.
Study: NCT01611350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RCT 3-Measure the Effects of Fuel Efficient Cookstoves on Health, Fuel Use and Time Spent Collecting Fuel
Description: Of those who accept the Novel Sales Offer, half the group will be randomly selected to start their free trial early while the other half will receive their free trial late. Those who receive their free trial late will serve as a control group for fuel consumption and Particulate Matter exposure in kitchens.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RCT 2- Testing the Effectiveness of the Novel Sales Offer and its ability to Increase Uptake of Purchasing Energy Efficient Cookstoves
Description: We are testing whether households who receive the Novel Sales Offer have higher uptake than those households who receive the Traditional Sales Offer.
Study: NCT00503880

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: subcutaneously one day prior to treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: single IV dose over 1 hour daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: subcutaneously daily for 5 days 2-4 hours following the end of the Clofarabine infusion

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Both standard cytogenetic testing and FISH (fluorescent in situ hybridization) are adequate to assess responses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: bone marrow biopsy
Study: NCT01252719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Vancomycin
Description: Intravenous vancomycin was administered for a minimum of 7 days and up to a maximum of 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous placebo was administered thereafter, for a minimum of 7 days and up to a maximum of 10 days (oritavancin and placebo).
Study: NCT02311920

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT03666481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Physical Activity Intervention (MPAI)
Description: MPAI was carried out during 6 consecutive months. The sessions were directed by sport sciences professionals, who were trained in the application of motivational strategies based on self-determination theory.~The frequency of training, as well as the duration of the sessions, was increasing throughout the 6 months. The contents of the sessions could be directed in two ways: sessions with activities to develop cardiorespiratory fitness and muscular strength, and playful sessions to enhance psychosocial aspects. Nevertheless, motivational strategies were implemented in both types of sessions.
Study: NCT03866018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted physical activity
Description: 12 sessions of one hour of adapted physical activity.
Study: NCT02359201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0018
Description: Oromucosal - Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0018
Description: Oromucosal - Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oromucosal - Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oromucosal - Single dose
Study: NCT02736682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose antibiotic
Description: Single dose arm receive 2g of IV Ceftriaxone and 500 mgs ofIntra venous Metronidazole given to the mothers 30-60 minutes pre operative.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple dose antibiotic
Description: Multiple dose arm receive 1 g of IV Cetriaxone plus 500 mgs during surgery and there after IV ceftriaxone once a day for 3 days and IV Metronidazole 500mgs during surgery and there after every 8 hours for 3 days.
Study: NCT02904668

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self-managmeent program
Description: One session was a session supervised by a physical therapist in the Faculty of Health Sciences. The program contents were educative information about chronic neck pain and healthy lifestyle habits (application of local heat/cold, and sleeping face down, using correct sitting posture, alternating body position, and using correct lifting technique (...), which were complemented by a problem-based session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-managmeent program
Description: One session was a session supervised by a physical therapist in the Faculty of Health Sciences. The program contents were educative information about chronic neck pain and healthy lifestyle habits (application of local heat/cold, and sleeping face down, using correct sitting posture, alternating body position, and using correct lifting technique (...), which were complemented by a problem-based session.
Study: NCT01064531

Intervention type: DEVICE
Intervention: MIS Femoral Neck Stem implant

Intervention type: DEVICE
Intervention: MIS Femoral Neck Stem implant
Study: NCT04999930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerochamber
Description: efficacy and patients satisfaction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerochamber
Description: efficacy and patients satisfaction
Study: NCT00887328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue Plasminogen Activator (Alteplase)
Description: 0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
Study: NCT03344978

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardboard Cot Care
Description: Infant maintained in reflective film-lined cot for a period of 24 hours. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after randomization. If temperatures found \< 36° C. at any time, an additional blanket and hat will be added to infant to improve temperature. Infant may be moved to incubator or radiant warmer. All other care will be standard of care at University Teaching Hospital, including warm delivery rooms, immediate drying, postponed bathing and weighing, early and exclusive breastfeeding, and Kangaroo Mother Care as continuously as possible.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Incubator Care
Description: Infant maintained in standard incubator for a period of 24 hours. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after randomization. If temperatures found \< 36° C. at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including warm delivery rooms, immediate drying, postponed bathing and weighing, early and exclusive breastfeeding, and Kangaroo Mother Care as continuously as possible.
Study: NCT02728011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scientific Brain Training (SBT)
Description: Cognitive training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tetris
Study: NCT02098421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Use of oxytocin while the Foley bulb is in place

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Use of oxytocin while the Foley bulb is in place
Study: NCT03476343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE OPTIMA MR430s with HDx/GE Electronics
Description: MRI scan
Study: NCT04108559

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesiologic Tape Group
Description: A mucoperiosteal flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 3-0 silk sutures.The kinesiologic tape will be prepared individually for each patient; it will be cut into three equal strips (approximately 1.6 cm in width) and placed between the clavicle and the tragus-commissura line. The patients will be invited after one week for removing the sutures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drain Group
Description: A mucoperiosteal flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 3-0 silk sutures. A plastic non-customised drain tube (2-cm long, 2-mm diameter) will be inserted into a vertical incision between the first and second molars and sutured to the vestibular mucosa. The patients will be invited after one week for removing the sutures.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Routine third molar extraction will be performed. No extra procedures will be done after surgery.
Study: NCT04214717

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DC-CIK combined with Chemotherapy
Description: Patients will receive 4 cycles of DC-CIK treatments combined with Chemotherapy within 8 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Patients will only receive Chemotherapy.
Study: NCT03083626

Intervention type: OTHER
Intervention: Cold pressor test
Description: The cold pressor test is a procedure used for examining pain threshold and tolerance by subjects placing their forearm in an ice bath. Each participant will take the CPT at 1 °C, 5°C, and 9°C. The first CPT will always be at 1 °C, to ensure participants tolerate the ice bath at the standard temperature. The order of the subsequent CPT at 5°C and 9°C, will be randomized to control for differential carry over effects. Participants will be instructed to say Pain when pain is initially detected (threshold). Then they will be asked to keep the immersed limb in the container until the pain can no longer be tolerated and say Stop and remove the arm from the water when tolerance is reached.

Intervention type: OTHER
Intervention: Cold pressor test
Description: The cold pressor test is a procedure used for examining pain threshold and tolerance by subjects placing their forearm in an ice bath. Each participant will take the CPT at 1 °C, 5°C, and 9°C. The first CPT will always be at 1 °C, to ensure participants tolerate the ice bath at the standard temperature. The order of the subsequent CPT at 5°C and 9°C, will be randomized to control for differential carry over effects. Participants will be instructed to say Pain when pain is initially detected (threshold). Then they will be asked to keep the immersed limb in the container until the pain can no longer be tolerated and say Stop and remove the arm from the water when tolerance is reached.